Focused On-demand Library for E3 ubiquitin-protein ligase pellino homolog 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HAT8

UPID:

PELI2_HUMAN

Alternative names:

RING-type E3 ubiquitin transferase pellino homolog 2

Alternative UPACC:

Q9HAT8; B2RDY5

Background:

E3 ubiquitin-protein ligase pellino homolog 2, also known as RING-type E3 ubiquitin transferase pellino homolog 2, plays a pivotal role in immune response regulation. It catalyzes the attachment of ubiquitin to substrate proteins, influencing TLR and IL-1 signaling pathways through interaction with IRAK kinases and TRAF6. This protein is crucial for IL1B-induced polyubiquitination of IRAK1 and NF-kappa-B activation, a key factor in inflammatory responses.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase pellino homolog 2 could open doors to potential therapeutic strategies.